Open Access
Med Sci (Paris)
Volume 36, Number 11, Novembre 2020
Page(s) 1095 - 1097
Section Forum
Published online 05 November 2020
  1. Fischer A, Dewatripont M, Goldman M. L’innovation thérapeutique, à quel prix ? Med Sci (Paris) 2020; 36 : 389–93. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  2. Vivot A, Jacot J, Zeitoun JD, et al. Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000–2015. Ann Oncol 2017 ; 28 : 1111–1116. [CrossRef] [PubMed] [Google Scholar]
  3. Del Paggio JC, Sullivan R, Schrag D, et al. Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks. Lancet Oncol 2017 ; 18 : 887–894. [CrossRef] [PubMed] [Google Scholar]
  4. Salas-Vega S, Shearer E, Mossialos E. Relationship between costs and clinical benefits of new cancer medicines in Australia, France, the UK, and the US. Soc Sci Med 2020; 258 : 113042. [Google Scholar]
  5. Vokinger KN, Hwang TJ, Grischott T, et al. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis. Lancet Oncol 2020; 21 : 664–70. [CrossRef] [PubMed] [Google Scholar]
  6. Schnipper LE, Davidson NE, Wollins DS, et al. Updating the American society of clinical oncology value framework: revisions and reflections in response to comments received. J Clin Oncol 2016 ; 34 : 2925–2934. [CrossRef] [PubMed] [Google Scholar]
  7. European Society for Medical Oncology. ESMO-magnitude of clinical benefit scale (ESMO-MCBS). [Google Scholar]
  8. Cherny NI, de Vries EGE, Dafni U, et al. Comparative assessment of clinical benefit using the ESMO-magnitude of clinical benefit scale version 1.1 and the ASCO value framework net health benefit score. J Clin Oncol 2019 ; 37 : 336–349. [CrossRef] [PubMed] [Google Scholar]
  9. Jordan B.. Une approche pragmatique pour gérer les traitements onéreux. Med Sci (Paris) 2017 ; 33 : 1121–1123. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  10. Prasad V, De Jesús K, Mailankody S. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol 2017 ; 14 : 381–390. [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.